Search Results
Your search for ,foR matches 32806 pages
Showing 25801 - 25850GM-CSF Boosts Survival Benefit of Ipilimumab in Metastatic Melanoma
For metastatic melanoma, the activity of ipilimumab can be boosted by the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine), according to a phase II study that found the combination improved overall survival, vs ipilimumab alone. The results were presented at the 2013...
MSKCC Community Mourns the Death of Trudy Nan Small, MD
Trudy Nan Small, MD, was a pediatric hematologist at Memorial Sloan-Kettering Cancer Center who specialized in the diagnosis and care of children undergoing hematopoietic stem cell transplantation for hematologic malignancies and those with life-threatening genetic disorders of the immune system....
Plasma Epstein-Barr Virus DNA a Potential Marker for Treatment Response in Advanced Hodgkin Lymphoma
Plasma Epstein-Barr Virus (EBV) DNA has prognostic significance in Hodgkin lymphoma, both prior to therapy and at 6 months of follow-up, according to results of a study published in Blood. “Plasma EBV-DNA positivity at month 6 is associated with particularly poor outcomes and may serve as an...
Replacing Animal Fat with Vegetable Fat May Reduce Mortality Risk in Men with Nonmetastatic Disease
“Among men with nonmetastatic prostate cancer, replacing carbohydrates and animal fat with vegetable fat may reduce the risk of all-cause mortality,” according to a prospective study of 4,577 men with nonmetastatic prostate cancer in the Health Professionals Follow-up Study. Vegetable fat intake...
Using Quality Indicators Can Improve Outcomes among Patients with Renal Cell Carcinoma
An expert panel of 13 urologic and medical oncologists worked together to identify 23 quality indicators for renal cell carcinoma, as described in an article in the Journal of Oncology Practice. “These 23 [quality indicators] will provide a means of evaluating the quality of [renal cell carcinoma]...
Cognitive Complaints after Breast Cancer Treatment and Neuropsychological Testing
About one in five patients who had completed primary breast cancer treatments but had not started endocrine therapy “had elevated memory and/or executive function complaints that were statistically significantly associated with domain-specific” neuropsychological test performances and depressive...
Survival Benefits of DCIS Management Strategies Compared
Overall survival benefits of six management strategies for ductal carcinoma in situ (DCIS) are within 1 year of each other, according to a disease simulation model integrating empirical data from published literature and quantifying the tradeoffs among the different management strategies with...
Erratum
In the June 10 issue of The ASCO Post, the article, “Study Questions Routine Use of Imaging after Treatment for Diffuse Large B-cell Lymphoma,” includes an error in an Expert Point of View box featuring an interview with Andrew D. Zelenetz, MD, PhD. Dr. Zelenetz is quoted as saying that at his...
Shiitake Mushroom
The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
Driven by the Past
When I was 9 years old, a bout of nausea, vomiting, and abdominal pain sent me to the emergency room. The physicians diagnosed appendicitis and rushed me to the operating room. But what the surgeon found instead was a 10-cm-wide, grade 2, immature teratoma. In 1968, treatment for malignant ovarian...
Effect of Radium-223 Dichloride in Breast Cancer Bone Metastasis Model
Radium-223 dichloride (Xofigo) is an alpha particle–emitting radiotherapeutic drug that mimics calcium and localizes to areas of high bone turnover, providing targeted therapy for skeletal metastasis. The drug was recently approved for treatment of patients with castration-resistant prostate...
Treating BRAF V600E Colorectal Cancer May Require Concomitant BRAF and PI3K/mTOR Inhibition
BRAF V600E mutations are associated with poor prognosis in colorectal cancer. A study by Coffee and colleagues examined PI3K/mTOR signaling in BRAF V600E colorectal cancer cell lines after BRAF inhibition as well as cell viability and apoptosis after combined BRAF and PI3K/mTOR inhibition. Western ...
SIDEBAR: Expect Questions about Programmed Death Receptors
In today’s high-tech, sci-fi–loving culture, “programmed death receptor” seems like a term apt to stir up public interest, particularly when those receptors are being “targeted” by “agents.” In this case, however, the agents are antibodies that target programmed death 1 (PD-1) receptor and disable...
'Spectacular' Results with Immunotherapies in Melanoma Galvanize the Oncology Community
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Much of the news about immunotherapy ...
Focus on the Society of Rhode Island Clinical Oncologists
Founded in 1994, just 1 year after ASCO launched the State/Regional Affiliate Program, the Society of Rhode Island Clinical Oncologists is one of ASCO’s oldest state affiliates. Like many other ASCO affiliates, the Providence-based group is facing a myriad of challenges, including ensuring...
SIDEBAR: Big Ten Cancer Research Consortium
Indiana University (Indiana University Melvin and Bren Simon Cancer Center) Northwestern University (Robert H. Lurie Comprehensive Cancer Center) Penn State University (Penn State Hershey Cancer Institute) Purdue University (Purdue University Center for Cancer Research) Rutgers University (The...
Big Ten Universities Join Together in Cancer Research Consortium
Leaders from cancer centers affiliated with the “Big Ten” universities joined together in launching the Big Ten Cancer Research Consortium on June 1 in Chicago. The group is uniting to transform cancer research through collaborative oncology trials that leverage the scientific and clinical...
Newly Approved Drugs and Indications
FDA has approved the following new drugs and/or indications in 2013: Denosumab (Xgeva subcutaneous injection) for giant cell tumor of bone. Lenalidomide (Revlimid capsules) for relapsed/refractory mantle cell lymphoma FDA approved. Trametinib (Mekinist tablets) for unresectable or metastatic...
Accountable Care Organizations May Be at Risk for New Medical Liabilities
The promotion of accountable care organizations, a crucial element in the Affordable Care Act, may result in liability risks, said H. Benjamin Harvey, MD, JD, a radiologist in the Department of Radiology at Massachusetts General Hospital, and I. Glenn Cohen, JD, Assistant Professor of Law at...
Gary L. Dillehay, MD, Is New President, Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) recently announced the appointment of Gary L. Dillehay, MD, FACNM, FACR, to 2013-2014 President, SNMMI, during the Society’s Annual Meeting in Vancouver. Dr. Dillehay is Professor of Radiology at Northwestern Memorial Hospital in...
Molecular Imaging Improves Care in Pediatric Glioma
The amino acid imaging agent, O-(2-[18F]-fluoroethyl)-L-tyrosine (F-18 FET), may improve upon standard magnetic resonance imaging (MRI) and its diagnostic benefit for imaging pediatric gliomas when conventional MRI is not sufficient, said researchers at the Society of Nuclear Medicine and Molecular ...
AMA Announces 2013-2014 Board of Trustees; Names Oncologist Barbara McAneny, MD, Chair-elect
The American Medical Association (AMA) recently introduced the 21 members of its Board of Trustees for the coming year following elections held during the Annual Meeting of the AMA House of Delegates. The new Chair of the AMA Board of Trustees is David O. Barbe, MD, MHA, a Family Medicine physician ...
American Geriatrics Society Presents Diane E. Meier, MD, the 2013 Edward Henderson Award
The American Geriatrics Society (AGS) presented Diane E. Meier, MD, the 2013 Edward Henderson Award in recognition of her many invaluable contributions to the field of geriatrics. Dr. Meier received the award and delivered the Henderson State-of-the-Art Lecture during AGS’ Annual Scientific Meeting ...
Oncology Meetings
July WIN 2013 Symposium: Personalized Cancer Therapy: From Innovation to ImplementationJuly 10-12 • Paris, FranceFor more information: www.winsymposium.org 12th International Congress on the Future of Breast CancerJuly 18-20 • Huntington Beach, CaliforniaFor more information:...
Results of AXIS Trial Indicate a Significant Improvement over Historical Survival Data in Renal Cell Carcinoma
The phase III open-label AXIS trial comparing axitinib (Inlyta) vs sorafenib (Nexavar) as second-line treatment for metastatic renal cell carcinoma has shown a significant difference in median progression-free survival (8.3 months in the axitinib group vs 5.7 months in the sorafenib group; hazard...
Progression of Renal Cell Carcinoma Linked to Shifts in Tumor Metabolism
Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma. Their findings demonstrate that normal...
SEER Analysis Shows Increased Survival with Surgery and Radiation Therapy in Metastatic Gastric Cancer
A Surveillance, Epidemiology, and End Results (SEER) database analysis reported by Ravi Shridhar, MD, PhD, and colleagues in Cancer indicates that patients receiving surgery and radiation therapy for metastatic gastric cancer have prolonged survival compared with those receiving either alone or...
Learning to Negotiate the Genomic Complexities of Cancer
The Cancer Genome Atlas (TCGA) Research Network recently reported the results of an integrated analysis of the genomic features of 373 endometrial carcinomas.1 This report joins previously published results of similar analyses in ovarian, breast, and colorectal cancers, squamous cell carcinoma of...
Integrated Genomic Characterization of Endometrial Carcinomas Suggests New Classification Scheme
As recently reported in Nature, investigators in The Cancer Genome Atlas Research Network performed an integrated genomic, transcriptomic, and proteomic characterization of 373 endometrial carcinomas, including 307 endometrioid and 66 serous or mixed histology cases, using array- and...
SIDEBAR: HPV Vaccine Reduces HPV Infection Rate in Girls
A study from the Centers for Disease Control and Prevention (CDC) looking at the prevalence of HPV infections in girls before and after the introduction of the HPV vaccine in 2006 found a significant reduction of 56% in infections among female teenagers aged 14 to 19. About 79 million Americans,...
Study Shows HPV Vaccine Reduced Rate of Infection in Teenage Girls by 56%
A new government study investigating the prevalence of human papillomavirus (HPV) infections in females aged 14 to 59 before and after the introduction in 2006 of the HPV vaccine found that the rate of the HPV infection dropped by 56%, decreasing from 11.5% in 2006 to 5.1% in 2010 among female...
Erlotinib in First-line Treatment of Metastatic NSCLC with EGFR Exon 19 Deletion or Exon 21 (L858R) Substitution
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 14, 2013, erlotinib (Tarceva) was approved for...
FDA Approves Denosumab to Treat Giant Cell Tumor of the Bone
The U.S. Food and Drug Administration (FDA) has expanded the approved use of denosumab (Xgeva) to treat adults and some adolescents with giant cell tumor of the bone, a rare and usually noncancerous tumor. Denosumab, which was granted orphan product designation, was reviewed under the FDA’s...
Investigational New Drug Application Filed for CFI-400945
Investigators from Princess Margaret Cancer Centre in Toronto and the University of California, Los Angeles, have submitted an Investigational New Drug (IND) application for CFI-400945, a novel drug candidate targeting the enzyme PLK4, which plays a crucial role in cell division. The news was...
SIDEBAR: Notes from the Lead Investigator
We conducted this study to clarify a hypothesis that had been generated from preclinical work and small clinical datasets. One additional background point that should be made is that although not all previously reported small datasets had demonstrated a relationship between PTEN expression and...
Outcomes with Adjuvant Trastuzumab in HER2-positive Breast Cancer Not Affected by PTEN Status
PTEN is a negative regulator of PI3K/AKT signaling. PI3K/AKT signaling can be activated by HER2, and it has been hypothesized that alteration in this pathway may affect sensitivity to trastuzumab (Herceptin). Preclinical data and some of the limited available clinical data suggest that loss or...
Immunohistochemistry Effectively Detects ALK Rearrangement in Non-small Cell Lung Cancer Study
ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer. It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors. Development of robust and...
Expert Point of View: Marc Lippman, MD and C. Kent Osborne, MD
An editorial by Marc Lippman, MD, Leonard M. Miller School of Medicine, University of Miami, and C. Kent Osborne, MD, Breast Center, Baylor College of Medicine, Houston,1 accompanied the study by Dawson and colleagues. These authors commented that the study’s key findings—that variation in the...
Measurement of Circulating Tumor DNA Shows Promise in Monitoring Metastatic Breast Cancer
Management of metastatic breast cancer requires monitoring of tumor burden to assess response to treatment, and there is a need for biomarkers that can measure tumor burden with high sensitivity and specificity. Assays measuring serum cancer antigen (CA) 15-3 and circulating tumor cells have been...
Melanomas Induced by BRAF Inhibitors
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that...
ASCO Answers Guides to Breast, Colorectal, Prostate, and Lung Cancer Now Available to Order
The ASCO Answers guides to cancer are designed to help patients newly diagnosed with cancer understand their disease and treatment options. These comprehensive, patient-friendly booklets contain trusted information about diagnosis, treatment, side effects, and the psychosocial effects of cancer....
New International Innovation Grant Directly Supports Research Projects in Developing Countries
The Conquer Cancer Foundation and ASCO International have just launched a new research funding opportunity, the Conquer Cancer Foundation of ASCO International Innovation Grant, which directly supports research being conducted by investigators in low- and middle-income countries. Advancing Cancer...
ASCO Issues Progress Report on Blueprint for Cancer Research
ASCO has released a Progress Report on the gains made toward achieving goals set forth in its landmark 2011 report, Blueprint for Transforming Clinical and Translational Cancer Research. The ASCO Blueprint laid out an innovative roadmap for the clinical research system to capitalize on the new...
Institute Initiatives Help Oncologists Integrate Evidence-based Guidelines in Practice
Building on ASCO’s longstanding commitment to drive quality, value, and accountability in cancer care, the Institute for Quality’s initiatives provide oncologists with resources to ensure that every patient receives the highest level of cancer care. Established in 2011, the Institute for Quality...
Business Summit Fosters Innovative Solutions to Oncology Market Challenges
To provide a forum for key cancer stakeholders to join with business, finance, and legal thought leaders to explore the future course for oncology, ASCO is co-hosting the seventh annual Cancer Center Business Summit on October 24 and 25 in Chicago, Illinois. Designed as a resource for the business...
2013 Breast Cancer Symposium to Offer Expanded Meet the Professor Sessions and New Fellows, Residents, and Junior Faculty Track
As a cancer care specialist, it can be easy to become hyperfocused on your area of expertise within your subspecialty. But that’s exactly what ASCO wants its members—in all specialties—to avoid. The theme of this year’s Breast Cancer Symposium—Multidisciplinary Perspectives on Clinical...
Radium-223 Dichloride for Castration-resistant Prostate Cancer with Symptomatic Bone Metastases
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 15, 2013, radium Ra 223 dichloride (Xofigo) was...
Molecular Landscaping of Acute Myeloid Leukemia: Are We Relearning the Past or Informing the Future?
Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease.1 This concept has been supported by more than 4 decades of studies showing distinct outcomes of subsets of patients that differ in age, disease type (primary vs secondary vs therapy-related), and cytogenetic and...
Genomic and Epigenomic Characterization of Acute Myeloid Leukemia
In a study by the Cancer Genome Atlas Research Network reported in The New England Journal of Medicine, genomes of 200 adult cases of de novo acute myeloid leukemia (AML) were analyzed by whole-genome sequencing (n = 50) or whole-exome sequencing (n = 150) to identify mutations and relationships...
Study Reports 25% of Women Don't Complete Recommended Breast Cancer Treatment
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the 5-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers. For many women with hormone...
